Does Retatrutide Reduce Inflammation?

Does retatrutide reduce inflammation? This is an active area of investigation, but the evidence remains early-stage. Retatrutide is an investigational triple-receptor agonist (GLP-1, GIP and glucagon) with no marketing authorisation in the UK or elsewhere, accessible only within authorised clinical trials. Exploratory data from a Phase 2 trial reported reductions in the inflammatory marker hsCRP, though these occurred alongside substantial weight loss, making it difficult to separate any direct anti-inflammatory effect from the metabolic consequences of fat reduction. This article summarises what current trial data show and what remains unknown.

What is retatrutide and how does it work in the body?

Retatrutide simultaneously activates GLP-1, GIP and glucagon receptors, distinguishing it from licensed GLP-1 agonists. It has no UK marketing authorisation and is accessible only within authorised clinical trials.

Retatrutide is an investigational medicine that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon receptors.^[1][12] It currently holds no marketing authorisation in the UK or anywhere else, and can be accessed only within an authorised clinical trial.^[1][12]

This triple-receptor mechanism distinguishes it from currently licensed GLP-1 receptor agonists and from dual GLP-1/GIP agonists such as tirzepatide (Mounjaro), though no head-to-head trials have been conducted and no direct comparisons can be drawn. GLP-1 receptor activation slows gastric emptying and promotes satiety; GIP receptor activation modulates insulin secretion and has been studied for effects on fat tissue; glucagon receptor activation is associated with increased energy expenditure and fat oxidation in preclinical and early clinical research.^[18][19] Together, these actions are hypothesised, on the basis of Phase 2 trial findings (Jastreboff et al., New England Journal of Medicine, 2023), to produce substantial reductions in body weight and improvements in metabolic parameters, though these remain investigational observations rather than established clinical outcomes.

Because adipose (fat) tissue is itself a source of pro-inflammatory signalling molecules called adipokines and cytokines, reductions in fat mass achieved through any mechanism may secondarily reduce systemic inflammation.^[7] Whether retatrutide produces anti-inflammatory effects beyond those attributable to weight loss alone is a question that current trial data have begun to explore, though the evidence base remains early-stage.

Retatrutide is not available through any pharmacy or prescriber outside a clinical trial setting. Anything sold online under this name is not a licensed product and may be falsified. The MHRA provides guidance on buying medicines safely online at gov.uk/buy-medicines-online-safely.

What have clinical trials reported about retatrutide and inflammation?

The Phase 2 trial (Jastreboff et al., NEJM, 2023) noted exploratory reductions in hsCRP alongside weight loss, but no trial has used inflammation reduction as a primary endpoint, so a direct anti-inflammatory effect is not established.

Clinical trial data on retatrutide and inflammation are limited, and no trial has yet been designed with reduction of inflammatory markers as its primary endpoint. The most detailed published evidence comes from a Phase 2 dose-ranging trial reported by Jastreboff et al. in the New England Journal of Medicine in 2023, which enrolled adults with obesity or overweight and assessed weight loss, metabolic outcomes and safety over 48 weeks.^[1]

Within that trial, participants receiving the highest doses of retatrutide achieved substantial reductions in body weight. Alongside weight loss, improvements were observed in metabolic markers including fasting glucose, insulin resistance measures and lipid profiles. Exploratory analyses noted reductions in high-sensitivity C-reactive protein (hsCRP), a widely used marker of systemic inflammation, in participants who lost the most weight. These findings were not pre-specified primary outcomes, and the trial was not powered to isolate an anti-inflammatory effect independent of weight reduction.

The Phase 3 programme includes the TRIUMPH series of trials (assessing retatrutide in adults with obesity) and the TRANSCEND programme (including TRANSCEND-T2D-1, which has reported results in adults with type 2 diabetes, published in The Lancet).^[2] These larger studies are generating additional metabolic and safety data, though comprehensive inflammatory biomarker data from the Phase 3 programme are not yet fully in the public domain. Where Phase 3 results have been reported, they have focused on weight loss and cardiometabolic endpoints rather than inflammation specifically.

It is therefore not possible, on the basis of currently published data, to conclude that retatrutide reduces inflammation through a mechanism separate from its effects on body weight and metabolic function. GLP-1 receptor agonists as a class have been associated with reductions in inflammatory markers in various studies, and the glucagon receptor component of retatrutide may influence hepatic fat and liver inflammation, but these remain mechanistic hypotheses rather than established clinical findings for this specific medicine.^[8][9]

What side effects and safety signals have trials identified?

The most common side effects are gastrointestinal, including nausea, vomiting and diarrhoea, consistent with the GLP-1 agonist class. Heart rate increases and injection-site reactions have also been reported in Phase 2 data.

The most commonly reported side effects of retatrutide in clinical trials have been gastrointestinal in nature, consistent with the GLP-1 receptor agonist class, and include nausea, vomiting, diarrhoea and constipation. These effects were generally dose-dependent and most frequent during dose escalation, tending to diminish over time. A small number of participants in the Phase 2 trial discontinued treatment due to gastrointestinal adverse events.

Acute pancreatitis has been reported with GLP-1 receptor agonist class medicines, including post-marketing reports of necrotising pancreatitis and reports with fatal outcomes.^[3] Whether retatrutide carries a comparable risk cannot be quantified from Phase 2 data alone. Anyone enrolled in a retatrutide trial who experiences severe or persistent abdominal pain should contact their trial team immediately, as this may require urgent evaluation.

Heart rate increases have been observed with retatrutide in the Phase 2 trial (Jastreboff et al., 2023), as with other medicines in this class, and cardiovascular safety is being assessed in the ongoing Phase 3 programme. Injection-site reactions have also been reported. Class-level signals observed with related licensed medicines, such as gallbladder events and dehydration, have not been established for retatrutide specifically and remain under investigation within the trial programme.

Because retatrutide is available only within authorised clinical trials, adverse events must be reported to the trial team under the study protocol. Trial participants are advised to carry their study identification card at all times and to show it to any emergency or urgent care clinician, informing them of their trial enrolment so that appropriate precautions can be taken. Suspected side effects of medicines can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; however, participants in a clinical trial should follow their study protocol for reporting, as the trial team and sponsor have specific obligations in this regard.

Women of childbearing potential are excluded from retatrutide trials if they are pregnant, breastfeeding or planning pregnancy. Contraception requirements apply to trial participants and are specified within each study protocol. Anyone with questions about eligibility or safety should speak to their trial investigator.

Does retatrutide reduce inflammation, or is the evidence still limited?

The evidence is still limited. Reductions in hsCRP observed in Phase 2 data occurred alongside substantial weight loss, and no trial has yet isolated an anti-inflammatory effect independent of fat reduction.

The honest answer is that the evidence is still limited. No regulatory body has evaluated retatrutide for an anti-inflammatory indication, because the medicine has not yet received a marketing authorisation anywhere in the world. Exploratory findings from the Phase 2 trial suggest that retatrutide is associated with reductions in markers such as hsCRP, but these changes occurred alongside very substantial weight loss, making it difficult to attribute any anti-inflammatory effect to the drug's pharmacology rather than to the metabolic consequences of losing body fat.

This distinction matters clinically. Excess adipose tissue drives chronic low-grade inflammation through the release of pro-inflammatory cytokines and adipokines. Any intervention that substantially reduces fat mass, whether dietary, surgical or pharmacological, tends to lower circulating inflammatory markers. To establish that retatrutide has an anti-inflammatory effect beyond weight loss, trials would need to compare inflammatory outcomes between groups losing equivalent amounts of weight by different means, or to identify mechanistic pathways, such as direct GLP-1 or glucagon receptor signalling in immune cells, that operate independently of fat reduction. Such trials have not yet been conducted or reported for retatrutide.

The ongoing TRIUMPH and TRANSCEND Phase 3 trials may generate more detailed biomarker data, but their primary endpoints relate to weight loss and cardiometabolic outcomes rather than inflammation specifically. Until those data are published and independently reviewed, any claim that retatrutide reduces inflammation as a distinct therapeutic effect goes beyond what the evidence supports.

For those seeking weight-management options now, licensed treatments are available and can be discussed with a GP. NHS availability of specific medicines depends on NICE guidance, national commissioning arrangements and local Integrated Care Board (ICB) pathways; private options also exist.^[15][16] Retatrutide itself remains accessible only to participants in authorised clinical trials, and no UK authorisation date can be given. Information on legitimate UK clinical trials can be found through the NIHR Be Part of Research portal at bepartofresearch.nihr.ac.uk.

Frequently Asked Questions